Journal
CELL HOST & MICROBE
Volume 29, Issue 12, Pages 1738-+Publisher
CELL PRESS
DOI: 10.1016/j.chom.2021.11.004
Keywords
-
Categories
Funding
- NIH/NIAID [HHSN272201700013C, R01AI127877, R01AI130398]
- NIH/NCI [1U54CA260517]
- Swiss National Science Foundation (SNSF)
Ask authors/readers for more resources
The study found marked differences in antibody responses among individuals in Mongolia vaccinated with different COVID-19 vaccines, with lower levels of antibodies stimulated by the Sinopharm and Sputnik V vaccines. Those who recover from infection after vaccination typically achieve high antibody titers.
Different SARS-CoV-2 vaccines are approved in various countries, but few direct comparisons of the antibody responses they stimulate have been reported. We collected plasma specimens in July 2021 from 196 Mongolian participants fully vaccinated with one of four COVID-19 vaccines: Pfizer/BioNTech, AstraZeneca, Sputnik V, and Sinopharm. Functional antibody testing with a panel of nine SARS-CoV-2 viral variant receptor binding domain (RBD) proteins revealed marked differences in vaccine responses, with low antibody levels and RBDACE2 blocking activity stimulated by the Sinopharm and Sputnik V vaccines in comparison to the AstraZeneca or Pfizer/BioNTech vaccines. The Alpha variant caused 97% of infections in Mongolia in June and early July 2021. Individuals who recover from SARS-CoV-2 infection after vaccination achieve high antibody titers in most cases. These data suggest that public health interventions such as vaccine boosting, potentially with more potent vaccine types, may be needed to control COVID-19 in Mongolia and worldwide.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available